ArticleMolecular biology reports2025
Dexpanthenol attenuates brain injury following pulmonary ischemia/reperfusion: modulation of oxidative stress, inflammation, and apoptotic pathways.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
A serious pathological condition known as pulmonary ischemia-reperfusion (I/R) injury can develop after procedures like cardiopulmonary bypass, pulmonary embolism, or lung transplantation. This process has a negative impact on distant organs, including the brain, and is linked to oxidative stress, apoptosis, and systemic inflammation. The purpose of this study was to assess the preventive effects of dexpanthenol (DEX) against pulmonary I/R injury-induced brain tissue damage in rats. Thirty-two male Wistar Albino rats were divided into four groups: control, IR (60 min of reperfusion and ischemia), IR + DEX (500 mg/kg), and DEX. After 60 min of reperfusion, the rats were sacrificed and brain, cerebellum and hippocampus tissues were taken. Histopathological and immunohistochemical analyses were performed on brain, cerebellum and hippocampus tissues. Genetic and biochemical analyses were performed on brain tissue to evaluate oxidative stress, apoptosis and inflammation. In addition to increased expressions of Caspase-3 (CASP3), inducible nitric oxide synthase (INOS), and tumor necrosis factor alpha (TNF-α), pulmonary I/R injury markedly increased hyperemia, edema, neuronal damage, and gliosis. Biochemical studies showed lower total antioxidant status (TAS) levels and higher oxidative stress index (OSI) and total oxidant status (TOS) values. According to a genetic research, anti-apoptotic genes were downregulated whereas pro-apoptotic genes were upregulated. DEX treatment reduced histopathological damage by 60% (p ≤ 0.001) and decreased TNF-α expression by 45% in brain tissue compared to the IR group. Oxidative stress markers (TOS, OSI) were lowered by 35–50%, while anti-apoptotic BCL2 expression increased 2.1-fold (p ≤ 0.01). By lowering inflammation, oxidative stress, and apoptosis, DEX showed strong neuroprotective benefits on brain and cerebellar damage resulting from pulmonary I/R injury. According to these results, DEX might be a useful medication for treating brain damage brought on by systemic inflammation.
Indexed as
Identifiers
40668442What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.